Setbacks For China Pharma As Firms Hit With Antitrust Fine, Clinical Setback

 
• By Brian Yang

One of China's largest domestic pharma conglomerates has been fined more than $100m for price-fixing and other monopoly acts, while another firm has seen a major Phase III setback for its global launch hope.

china and antitrust
YANGZTE RIVE PHARMA BECOMES THE TARGET IN CHINA ANTITRUST CRACKDOWN • Source: Shutterstock

More from China

More from Focus On Asia